Consistently, oral administration of INCB059872 (FAD-directed covalent inhibitor of LSD1) in the 4T1 mammary cancer model significantly inhibits polymorphonuclear (PMN)-MDSC differentiation and increased intratumoral T lymphocyte infiltration [97]. Here, KDM1A is linked to breast cancer.